Merrimack Pharmaceuticals is an integrated, biopharmaceutical company committed to the innovation of life-enhancing medicines for the treatment of autoimmune disease and cancer. Merrimack is advancing a range of clinical and early-stage biologics that represent the next generation of patient-directed, targeted therapies. Their work is founded on a proprietary Network Biology research engine. Their lead product, MM-121, is currently in Phase 1 clinical trials for the treatment of oncology patients.
